Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China
Real-World Effectiveness and Safety of Deutetrabenazine in Chinese Patients With Chorea Associated With Huntington's Disease.
The Primary Objective: To evaluate the real-world effectiveness of deutetrabenazine in adult participants with chorea associated with Huntington's disease in China.
The Secondary Objectives: To evaluate the real-world safety of deutetrabenazine in adult participants with chorea associated with Huntington's disease in China.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Beijing, Porcelana, 100053
- Teva Investigational Site 03
-
Beijing, Porcelana, 100070
- Teva Investigational Site 02
-
Chengdu, Porcelana, 610041
- Teva Investigational Site 01
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Participants with clinically confirmed diagnosis of chorea associated with Huntington's Disease (HD)
- Participants whose baseline total maximal chorea (TMC) score ≥ 8
- Participants who are deutetrabenazine-naïve before study entry or who did not receive deutetrabenazine within 30 days of study entry, and who are about to be treated with deutetrabenazine for chorea associated with HD
- Participants who have provided written consent for the use of personal and medical information for study purposes
Exclusion Criteria:
- Participants who have an unstable or serious medical or psychiatric illness at baseline
- Participants with any history of suicidality, untreated or inadequately treated depression
- Participants with certain comorbidities, including hepatic impairment, congenital long QT syndrome, and clinically significant cardiac arrhythmias.
- Participants who received reserpine within 20 days of deutetrabenazine treatment initiation
- Participants who received monoamine oxidase inhibitors within 14 days of deutetrabenazine treatment initiation
- Participants who received vesicular monoamine transporter 2 (VMAT2) inhibitors, e.g., tetrabenazine or valbenazine, within 30 days of deutetrabenazine treatment initiation
- Participants unable to provide a written consent for the study.
- Participants who are participating in another study that includes treatment with an investigational drug and/or intervention at the same time as enrolment in the current study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Deutetrabenazine
|
deutetrabenazine tablets
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change From Baseline in TMC Score in Participants Receiving ≥24 mg/Day
Periodo de tiempo: Baseline, Week 16
|
The TMC score was determined from Item 12 of the motor assessment (Part 1) of the UHDRS and quantifies chorea (range, 0-28, lower score indicated less chorea).
It was the sum of maximal chorea scores for 7 body regions (face, buccal-oral-lingual, trunk, and 4 extremities), each of which was scored on a scale from 0 to 4 (0, absent; 1, slight or intermittent; 2, mild and common or moderate and intermittent; 3, moderate and common; and 4, marked and prolonged).
|
Baseline, Week 16
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Any Adverse Events (AEs) By Severity Grade
Periodo de tiempo: Baseline up to Week 16
|
AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Severity of AEs recorded as one of following Common Terminology Criteria for Adverse Events (CTCAE) criteria: -Grade 1: Mild; asymptomatic or mild symptoms; clinical/diagnostic observations only; intervention not indicated.
-Grade 2: Moderate; local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL) (for example, preparing meals, shopping for groceries or clothes, using telephone).
-Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization; disabling; limiting self-care ADL (bathing, dressing, feeding self, using toilet, taking medications, and not bedridden).
-Grade 4: Life-threatening; urgent intervention indicated.
-Grade 5: Death related to AE.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With Serious Adverse Events (SAEs)
Periodo de tiempo: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
The SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With Treatment-related AEs
Periodo de tiempo: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Number of participants with treatment-related AEs is reported in this outcome measure.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With AEs Leading to Dose Reduction, Interruption, Treatment Discontinuation, and Study Withdrawal
Periodo de tiempo: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Number of participants with AEs leading to dose reduction, interruption, treatment discontinuation, and study withdrawal is reported in this outcome measure.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With AEs in Titration Phase
Periodo de tiempo: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
AEs lasted from titration phase to maintenance phase were considered an AE that occurred in the titration phase.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With AEs in Maintenance Phase
Periodo de tiempo: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Number of Participants With AEs of Special Interest
Periodo de tiempo: Baseline up to Week 16
|
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
AEs of special interest included suicidality, depression, somnolence, QTc prolongation, akathisia, and parkinsonism.
A summary of other non-serious AEs and all serious AEs, regardless of causality is located in the Reported AE section.
|
Baseline up to Week 16
|
|
Change From Baseline in TMC Score in All Participants Regardless of Study Drug Dose
Periodo de tiempo: Baseline, Week 16
|
The TMC score was determined from Item 12 of the motor assessment (Part 1) of the UHDRS and quantifies chorea (range, 0-28, lower score indicated less chorea).
It was the sum of maximal chorea scores for 7 body regions (face, buccal-oral-lingual, trunk, and 4 extremities), each of which was scored on a scale from 0 to 4 (0, absent; 1, slight or intermittent; 2, mild and common or moderate and intermittent; 3, moderate and common; and 4, marked and prolonged).
|
Baseline, Week 16
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Teva Medical Expert, MD, Teva Branded Pharmaceutical Products R&D LLC
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Manifestaciones neurológicas
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Desordenes mentales
- Enfermedades Genéticas Congénitas
- Trastornos neurocognitivos
- Trastornos cognitivos
- Demencia
- Enfermedades neurodegenerativas
- Trastornos del movimiento
- Trastornos Heredodegenerativos, Sistema Nervioso
- Enfermedades de los ganglios basales
- Discinesias
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Enfermedad de Huntington
- Corea
- deutetrabenazina
Otros números de identificación del estudio
Otros números de identificación del estudio
- TV50717-NDG-40182
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .